Eli Lilly and Company (NYSE:LLY) is Empirical Asset Management LLC’s 3rd Largest Position

Empirical Asset Management LLC boosted its position in Eli Lilly and Company (NYSE:LLY) by 0.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,150 shares of the company’s stock after buying an additional 138 shares during the quarter. Eli Lilly and Company makes up approximately 5.6% of Empirical Asset Management LLC’s portfolio, making the stock its 3rd biggest position. Empirical Asset Management LLC’s holdings in Eli Lilly and Company were worth $44,430,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of LLY. Adamsbrown Wealth Consultants LLC bought a new stake in Eli Lilly and Company in the third quarter valued at approximately $222,000. Oxler Private Wealth LLC lifted its position in Eli Lilly and Company by 0.5% in the third quarter. Oxler Private Wealth LLC now owns 6,050 shares of the company’s stock valued at $5,360,000 after purchasing an additional 28 shares during the last quarter. ORG Wealth Partners LLC bought a new stake in Eli Lilly and Company in the third quarter valued at approximately $1,187,000. Woodstock Corp lifted its position in Eli Lilly and Company by 1.5% in the third quarter. Woodstock Corp now owns 8,151 shares of the company’s stock valued at $7,221,000 after purchasing an additional 122 shares during the last quarter. Finally, Svenska Handelsbanken AB publ bought a new stake in Eli Lilly and Company in the third quarter valued at approximately $33,172,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Morgan Stanley restated an “overweight” rating and set a $1,106.00 target price on shares of Eli Lilly and Company in a report on Tuesday, August 27th. BMO Capital Markets upped their target price on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Truist Financial upped their target price on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a report on Thursday. Evercore ISI upgraded Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $1,025.00 target price on shares of Eli Lilly and Company in a report on Thursday, October 3rd. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average price target of $979.29.

Eli Lilly and Company Stock Down 0.5 %

Shares of NYSE LLY traded down $4.82 during trading on Monday, reaching $927.24. The company had a trading volume of 305,591 shares, compared to its average volume of 2,995,901. Eli Lilly and Company has a 12-month low of $547.61 and a 12-month high of $972.53. The stock has a market cap of $881.25 billion, a PE ratio of 137.27, a P/E/G ratio of 2.79 and a beta of 0.42. The business’s 50-day moving average is $910.84 and its 200 day moving average is $853.38. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The firm had revenue of $11.30 billion for the quarter, compared to analysts’ expectations of $9.83 billion. As a group, equities analysts forecast that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.